A EFFACER

Description Results NMA

OS 0.96 [0.76; 1.21]

PFS 1.04 [0.84; 1.29]

OS 0.84 [0.66; 1.07]

PFS 0.84 [0.67; 1.06]

DMFS 0.84 [0.66; 1.07]

PFS 0.87 [0.76; 1.00]

OS 0.96 [0.83; 1.12]

DMFS 0.93 [0.81; 1.07]

PFS 0.77 [0.62; 0.95]

OS 0.91 [0.72; 1.15]

rIFN-alpha2b (n=-9)

vs.

observation (n=-9)

4 arms: IFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation

Sample size: -9/-9

Primary endpoint:

FU duration: 8.2 years (median)

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 4.65 years

pegylated interferon alfa-2b 6 mug/kg per week for 8 weeks (induction) then 3 mug/kg per week (maintenance) for an intended duration of 5 years (n=627)

vs.

(n=629)

Sample size: 627/629

Primary endpoint: recurrence-free survival

FU duration: 3.8 years

intermediate-dose interferon alfa-2b duration 1 (n=-9)

vs.

duration 2 (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: 72·4 months

recurrence free survival 0.76 [0.64; 0.90] Demonstrated

OS 0.72 [0.58; 0.89]

PFS 0.76 [0.64; 0.90]

distant metastasis free survival 0.76 [0.63; 0.91]

grade 3-4 2.07 [1.74; 2.46]

ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses, then every 3 months for up to 3 years or until disease recurrence or an unacceptable level of toxic effects occurred (n=475)

vs.

placebo (n=476)

double-blind

Parallel groups

Sample size: 475/476

Primary endpoint: RFS

FU duration: 5.3 years

phase 3

recurrence free survival 0.65 [0.51; 0.83] Demonstrated

PFS 0.65 [0.51; 0.83]

Adverse events leading to discontinuation of drug 0.23 [0.17; 0.31]

Grade 3 or 4 drug-related adverse events 0.31 [0.24; 0.40]

nivolumab at a dose of 3 mg per kilogram of body weight every 2 weeks (n=453)

vs.

ipilimumab at a dose of 10 mg per kilogram every 3 weeks for four doses and then every 12 weeks (n=453)

double-blind

Parallel groups

Sample size: 453/453

Primary endpoint: Recurrence free survival

FU duration: 18 months (median)

recurrence free survival 0.57 [0.43; 0.75] Demonstrated

PFS LP-D1 positif 0.54 [0.42; 0.69]

PFS PD-L1 negatif 0.47 [0.26; 0.85]

PFS 0.57 [0.43; 0.75]

Grade 3 or 4 drug-related adverse events 4.35 [2.61; 7.26]

Vitiligo any grade 2.96 [1.34; 6.52]

Vitiligo grade 3-4 NaN [NaN; NaN]

Pembrolizumab (Participants receive pembrolizumab 200 mg intravenously (IV) on Day 1 of each 21-day cycle for up to 1 year) (n=514)

vs.

placebo (n=505)

double-blind

Parallel groups

Sample size: 514/505

Primary endpoint: Recurrence-free survival ,

FU duration: 15 months (median)

OS 0.57 [0.42; 0.78]

PFS 0.47 [0.39; 0.57]

distant metastasis free survival 0.51 [0.40; 0.65]

dabrafenib (150 mg twice daily) and trametinib (2 mg once daily) orally for 12 months (n=-9)

vs.

placebo (n=-9)

double-blind

Sample size: -9/-9

Primary endpoint: Relapse-free survival

FU duration:

(n=-9)

vs.

(n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration:

PFS 0.65 [0.50; 0.85]

OS 0.72 [0.49; 1.08]

e twice-daily adjuvant oral vemurafenib 960 mg tablets for52 weeks (13×28-day cycles) (n=-9)

vs.

placebo (n=-9)

Sample size: -9/-9

Primary endpoint:

FU duration: